ImmuCell Q2 revenue rises on higher distributor volume, price realization

ImmuCell

13/08/2026 21:14

Overview
Animal health biologics firm's Q2 revenue rose 11.5% yr/yr to $7.2 mln
Q2 net income increased to $1.8 mln, aided by $2 mln legal settlement
Company to invest $8 mln in First Defense capacity expansion over two phases

Outlook
ImmuCell expects to complete $3.5 mln freeze-drying capacity investment in first half of 2027
Company plans $4.5 mln investment in colostrum processing capacity, expected to take six months
ImmuCell expects to triple capacity and improve product economics over next 18 months

Result Drivers
DISTRIBUTOR VOLUME AND PRICING - Co said Q2 revenue growth was driven by higher distributor out-the-door volume and price realization across sales territories and products
GROSS MARGIN PRESSURE - Q2 gross margin declined due to lower manufacturing volumes, costs from a discontinued development program, and scrap from a quality issue with purchased material
LEGAL SETTLEMENT IMPACT - Net income benefited from a one-time $2 mln settlement from a former contract manufacturer, shown as a reduction to operating expenses

Company press release: ID:nGNX5kLXgY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
 
$0.20
 
Q2 Net Income
 
$1.84 mln
 
Q2 Operating Expenses
 
$502,000
 
Q2 Pretax Profit
 
$1.88 mln
 

Reuters Recommended Reads
Aug 13 - Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs 
Aug 10 - New Zealand's PGG Wrightson FY26 revenue rises, net profit up 46% on record livestock, property sales
Aug 13 - Biofrontera Q2 revenue rises on higher volume, pricing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)